By taking out Abide Therapeutics, Lundbeck has bought one of very few clinical-stage Tourette’s syndrome candidates.
Abbvie will need more than Skyrizi and upadacitinib to fill a Humira-shaped hole, and there are a few early-stage candidates it reckons could fit the bill.
The upcoming American Academy of Neurology meeting could provide clues on how the market will shake out.
The companies’ decision to start a 1,500-patient Alzheimer’s disease study defies logic.
Scholar Rock selects a lead molecule inhibiting TGF-β, an increasingly important oncology mechanism that Glaxosmithkline recently paid €300m to enter.
Five months after Allogene’s flotation there are few signs of waning interest in new issues of cell therapy companies, and they all have one thing in common.
Eidos presses ahead in its David and Goliath battle against Pfizer in amyloidosis, but it could have issues with pivotal trial recruitment.
The first sickle cell and beta thalassaemia patients have been enrolled into a Crispr/Cas9 trial, heating up a race with Bluebird, Sanofi, Sangamo and Editas.
The acquisition marked Astrazeneca’s formal embrace of biologicals. Today the Medimmune name was dropped.